Search Results
Aug 13, 2026, 09:10 ET IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
experts that reinforce the growing clinical role of cryoablation in breast cancer treatment de-escalation. A new review cites ProSense®'s U.S. Food and Drug Administration ("FDA") marketing authorization, its inclusion in updated American Society of Breast Surgeons ("ASBrS") guidelines and encouraging outcomes
More news about: IceCure Medical
Aug 13, 2026, 09:07 ET Liviniti and BlueGenes Collaborate for Safer, More Effective Medication Management
NATCHITOCHES, La., Aug. 13, 2026 /PRNewswire/ -- Liviniti, a national leader in PBM transparency and prescription drug savings, today announced its collaboration with the precision medicine company, BlueGenes, offering members access to cutting-edge pharmacogenomic (PGx)
More news about: Liviniti
Aug 13, 2026, 09:00 ET New CareCredit Research Finds Americans Want to Stay Active and Age Well, but Many Overlook Chiropractic Care
STAMFORD, Conn., Aug. 13, 2026 /PRNewswire/ -- Americans increasingly value prevention, mobility and drug-free approaches to staying healthy, yet new national research commissioned by CareCredit, a health and wellness financial solution from
More news about: Synchrony
Aug 13, 2026, 09:00 ET NATIONAL COMPASSIONATE CARE COUNCIL ANNOUNCES SCIENTIFIC COLLABORATION WITH STANDARD SEED CORPORATION
designed to operate across distinct regulatory categories, including lawful hemp-derived products, state-regulated cannabis products, and FDA-regulated drug development.Among NCCC's current priorities is evidence generation relevant to the CMS Innovation Center's Substance Access Beneficiary Engagement
More news about: National Compassionate Care Council
Aug 13, 2026, 09:00 ET In Rural Oregon, the Pharmacist Is Often the Closest Thing to Healthcare Access
a simple, confidential web page where patients can request to start counseling on their own time - modeled after the page already live for Red Cross Drug Store, a fellow CPG pharmacy in La Grande, at
More news about: Cascadia Pharmacy Group
Aug 13, 2026, 08:15 ET Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
engineered with Pulmatrix's iSPERSE™ dry powder inhalation technology for the treatment of acute migraine has a Food and Drug Administration acceptance of an Investigational New Drug ("IND") application for PUR3100 and receipt of a "study may proceed" letter to proceed with a Phase 2 study. The IND includes
More news about: Pulmatrix Inc.
Aug 13, 2026, 08:05 ET Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC), as detected by a U.S. Food and Drug Administration (FDA)-authorized test, with disease progression following at least one line of endocrine therapy. "The commercial
More news about: Rigel Pharmaceuticals, Inc.
Aug 13, 2026, 08:01 ET NextPlat Reports 21% Sequential Quarterly Revenue Growth, 87% Reduction in Quarterly Net Loss to $144,000 and Record Gross Margin of Approximately 40%
period. The increase was primarily attributable to the addition of new contracted medication fulfillment services and lower drug acquisition costs resulting from the Medicare Drug Price Negotiation Program, which commenced in January 2026. With higher-margin 340B contracted services revenue expected to
More news about: NextPlat Corp.
Aug 13, 2026, 08:00 ET Curis, Inc. Announces Pricing of $5.6 Million Public Offering
complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through
More news about: Curis, Inc.
Aug 13, 2026, 08:00 ET Vesalio Announces FDA 510(k) Clearance of pVasc NET, a Next-Generation Peripheral Mechanical Thrombectomy Device with Integrated Distal Filter
Aug. 13, 2026 /PRNewswire/ -- Vesalio, a global leader in vascular intervention, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for pVasc NET, a next-generation peripheral mechanical thrombectomy device featuring an integrated
More news about: Vesalio
Aug 13, 2026, 08:00 ET Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome,
More news about: Atrium Therapeutics
Aug 13, 2026, 08:00 ET Ann & Robert H. Lurie Children's Hospital of Chicago and Clearway Health Celebrate Opening of Hospital's First Specialty Pharmacy
hiring and embedding skilled pharmacists and patient liaisons into the clinical team.Deliver proprietary software technology.Unlock drug access and lead accreditation processes.Grow revenue at healthy margins for health systems and reduce costs for patients.To learn
More news about: Clearway Health
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
Company's myelofibrosis program. Following continued constructive engagement with the U.S. Food and Drug Administration (FDA), the Company remains on track to submit its planned supplemental New Drug Application (sNDA) in August under the Accelerated Approval pathway for selinexor in combination with
More news about: Karyopharm Therapeutics Inc.
Aug 13, 2026, 07:30 ET ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
anticipates growth starting in 2027.Recently, the Company held a pre-supplemental Biologics License Application (sBLA) meeting with the U.S. Food and Drug Administration (FDA), during which the LOTIS-5 data was discussed. Following FDA meeting feedback regarding the benefit-risk observed in the LOTIS-5
More news about: ADC Therapeutics SA
Aug 13, 2026, 07:00 ET Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
and dysregulation of NOD/RIPK2 is implicated in several inflammatory and autoimmune diseases. AC-101 was developed from Accro Bioscience's proprietary drug discovery platform targeting regulatory cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China,
More news about: Accro Bioscience Inc.
Aug 13, 2026, 04:12 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Aug 12, 2026, 21:00 ET ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been approved by the National Medical Products Administration (NMPA) of China, making AK0406 the first influenza AFC drug to enter clinical
More news about: Shanghai Ark Biopharmaceutical Co., Ltd.
Aug 12, 2026, 21:00 ET ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been approved by the National Medical Products Administration (NMPA) of China, making AK0406 the first influenza AFC drug to enter clinical
More news about: Shanghai Ark Biopharmaceutical Co., Ltd.
Aug 12, 2026, 20:17 ET XtalPi Holdings Limited to Announce 2026 Interim Results on August 19, 2026
from the Massachusetts Institute of Technology (MIT). The company is a technology platform focused on quantum physics-based and AI-driven innovation in drug and materials discovery. By integrating quantum physics, artificial intelligence, cloud computing, and large-scale automation, XtalPi provides research
More news about: XtalPi Holdings Limited
Aug 12, 2026, 16:05 ET Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
comments raised in the EOP2 meeting written response.Completed the validation and certification of essential lot release assays for drug substance and drug product.Completed four engineering runs of AP-SA02 at the Company's in-house current Good Manufacturing Practices ("cGMP") manufacturing
More news about: Armata Pharmaceuticals, Inc.
Aug 12, 2026, 16:05 ET INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026Commercial preparations
More news about: INOVIO Pharmaceuticals, Inc.
Aug 12, 2026, 16:05 ET Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).This release is intended for investors only. For additional information about Talphera, please visit
More news about: Talphera, Inc.
Aug 12, 2026, 16:01 ET PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
associated with chronic Enzyme Replacement Therapy (ERT). ST-920 has received Regenerative Medicine Advanced Therapy (RMAT) designation as well as Orphan Drug and Fast Track designations from FDA.The Phase 1/2 STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR)
More news about: PTC Therapeutics, Inc.
Aug 12, 2026, 16:00 ET AWH Reports Second Quarter 2026 Financial Results
split of the Company's Class A common stock in support of a planned uplisting to a major U.S. exchange.Submitted applications with the U.S. Drug Enforcement Administration ("DEA") to register certain state-licensed medical cannabis operations under the expedited registration pathway established
More news about: Ascend Wellness Holdings, Inc.
Aug 12, 2026, 15:12 ET BioCare Earns Fourth Consecutive Inc. 5000 Recognition as New Model for Independent Specialty Drug Distribution Gains Momentum
continued growth, driven by strategic investments and innovative partnerships, including the BioCareSD and AllyGPO alliance, which has reimagined specialty drug distribution and group purchasing for independent community oncology and retina practices. Together, the organizations deliver
More news about: BioCare